U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06794008) titled 'BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases' on Jan. 06.
Brief Summary: The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
Study Start Date: Dec. 26, 2024
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Inflammatory Myopathy
Systemic Sclerosis (SSc)
ANCA-associated Vasculitis
IgG4-Related Diseases
Antiphospholipid Syndrome
Acquired Thrombotic Thrombocytopenic Purpura
Behcet Disease
Sjogren Syndrome
Intervention:
DRUG: BCMA-CD19 CAR-T therapy
Patients received the BCMA-CD19-ta...